US FDA 2009 drug safety warnings analysed

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2012年 / 1388卷 / 1期

关键词：

Regulatory Action; Suicidal Behaviour; Bupropion; Varenicline; Efalizumab;

D O I：

10.2165/00128415-201213880-00011

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：4 / 4

相关论文

共 50 条

[31] US FDA issues final guidance for issuing public warnings/notices
[J]. Reactions Weekly, 2019, 1741 (1) : 2 - 2
[32] US FDA: warnings about risks of abuse, addiction for all benzodiazepines
[J]. Reactions Weekly, 2020, 1825 (1) : 9 - 9
[33] US FDA backs safety of triazolam
[J]. Reactions Weekly, 1997, 682 (1) : 2 - 2
[34] US FDA reviewing safety of orlistat
[J]. Reactions Weekly, 2009, 1267 (1) : 3 - 3
[35] US FDA reviewing safety of cefepime
[J]. Reactions Weekly, 2007, 1179 (1) : 5 - 5
[36] US FDA reviews safety of Stalevo
[J]. Reactions Weekly, 2010, 1297 (1) : 2 - 2
[37] IMPACT OF FDA SAFETY WARNINGS ON SUBSEQUENT DIABETES CARE FOR USERS OF ROSIGLITAZONE
Huse, D.
Bizier, R.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A402 - A403
[38] The effects of drug safety warnings on drug sales and share prices
Bialkowski, Jedrzej
Clark, Jeremy
[J]. HEALTH ECONOMICS, 2022, 31 (01) : 174 - 196
[39] US to require safety warnings for Essure sterilization device
McCarthy, Michael
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2016, 352
[40] Roche, FDA announce new drug-interaction warnings for mibefradil
不详
[J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1998, 55 (03) : 210 - 210

← 1 2 3 4 5 →